Shanghai Fosun Pharmaceutical Group Co Ltd

Fosun’s KAT6A/B inhibitor enters phase‑I trials, targeting solid tumours with a novel epigenetic mechanism and early safety data from China’s SDA approval.

Fosun Pharma’s new Jinan Fund stake transfer and drug registration approval signal strategic growth, boosting investor confidence in its innovation‑driven portfolio.

Shanghai Fosun Pharmaceutical’s new drug approval and Pfizer partnership put it in line for early market entry, patent‑cliff protection, and strong global revenue potential.

Fosun Pharma launches Phase‑I trials for FXS887, a novel oral agent targeting solid tumours, sparking investor interest and highlighting the rise of unique, cost‑effective anticancer drugs.

Shanghai Fosun Pharmaceutical Group Co Ltd has announced a strategic divestment of its stake in Shanghai Clon, a move aimed at sharpening its focus on core drug development and optimizing asset allocation in a dynamic healthcare market.

Shanghai Fosun Pharmaceutical Group Co Ltd is navigating a bearish market trend in the pharmaceutical sector, driven by macroeconomic uncertainties and geopolitical tensions, but its stable stock performance and robust market capitalization suggest …

The share price of Shanghai Fosun Pharmaceutical Group Co Ltd surged 3.2% to 42.30 CNY, driven by a combination of positive sector sentiment, strong company fundamentals, and supportive analyst commentary.

Shanghai Fosun Pharmaceutical Group Co Ltd’s stock has experienced a moderate increase due to demand for innovative pharmaceuticals and the company’s solid financial performance, with a positive outlook expected to sustain upward momentum.

Fosun Pharmaceutical has reported a 38.96% year-over-year increase in net profit, driven by its focus on innovation and internationalization in key therapeutic areas.

Shanghai Fosun Pharmaceutical Group Co Ltd reported a 38.96% year-on-year increase in net profit to 17.02 billion yuan, driven by revenue growth and significant investment in research and development.